BCG-EVs
Candidate Overview
This vaccine comprises EVs derived from Mycobacterium bovis and Escherichia coli Nissle 1917. BCG-EVs carry multiple molecules, including known protective TB antigens. The EVs will be lyophilized to ensure physicochemical stability and eliminate the need for a cold chain. Owing to their acellular nature, the vaccine is suitable for infants and children, including those living with HIV.
Sponsor / Lead Developer: National Institute of Infectious Diseases, Japan Institute for Health Security
Development partner(s): TuBerculosis Vaccine Initiative (TBVI), Niigata University, Osaka Metropolitan University
Primary Indication: Prevention of Mtb infection or sustained infection
Other Indication(s): Prevention of TB disease and Prevention of TB recurrence
Target Population(s): Adolescents, Adults, Children, Elderly, Infants, People living with HIV, and People with Mtb infection
Target Route of Administration: Intranasal
Immune tissue localization: Lung and Upper respiratory tract
Immunological responses: B-cell/Antibody and T-cell
Preclinical Animal Models: Mouse
Intended to elicit trained immunity: Yes
Additional Immunologic Response Information
HYPOTHESIZED | DEMONSTRATED |
|
| Immune Response | B-cell/Antibody | T-cell |
| T-cell phenotype | (phenotyping ongoing) | |
| T-cell functional profile | IFN-γ |
|
| Characteristics of B-cell response | Mucosal IgA Systemic IgG | |
| Preferential immune tissue localization | Lung Upper respiratory tract |
|
| Trained immunity | Yes | |
Related Publications
- BCG-derived acellular membrane vesicles elicit antimycobacterial immunity and innate immune memory. (Front. Immunol., 2025)